基于68Ga-DOTATATE PET/CT与18F-FDG PET/CT的高分化肺类癌分子影像表型的诊疗一体化意义
本研究回顾性分析了经活检证实的典型类癌(TC)与非典型类癌(AC)患者的68Ga-DOTATATE与18F-FDG PET/CT分子影像表型,按双示踪剂摄取情况分为4种评分模式,发现TC与AC在双示踪剂上呈现广泛的患者间表型异质性,约半数患者(TC 46%、AC 53%)的表型不适合肽受体放射性核素治疗(PRRT),双示踪剂分子影像表型可用于筛选最适合PRRT的患者。
要点
- TC与AC在68Ga-DOTATATE与18F-FDG PET/CT上呈现广泛的患者间表型异质性。
- 约半数患者(TC 46%、AC 53%)的分子影像表型不适合PRRT。
- 双示踪剂分子影像表型可用于筛选最适合PRRT的患者。
核心结论
- TC与AC在GaTATE与FDG上呈现广泛的患者间表型异质性,约半数患者(TC 46%、AC 53%)具有不适合PRRT的表型。
- 双示踪剂分子影像表型可用于选择最适合PRRT的患者。
研究设计与样本
- 回顾性分析经活检证实的TC或AC患者,均在初诊时接受GaTATE与FDG PET/CT检查。
- 共纳入56例患者(中位年龄66.5岁,女性32例),其中TC 22例、AC 34例。
- 以肝脏实质摄取为阳性阈值,结合同期CT或MRI,将每例患者的分子影像表型分为评分1至4。
主要发现
- 远处转移见于32%的TC与94%的AC。
- TC中位随访37个月、AC中位随访38个月时,TC与AC的生存率分别为100%与63%。
- AC的中位总生存期为56个月(95%CI 43,未达到[NR]),TC的中位总生存期未达到。
- 患者间双示踪剂分析中,TC的评分1、2、3、4分别占23%、18%、36%、23%;AC分别占3%、15%、32%、50%。
- 16例接受PRRT的患者(评分2者3例、评分3者12例、评分4者1例)3个月疾病控制率为85%,总生存期为54.6个月(95%CI 44-70)。
关键数值与推荐
- 评分1定义为所有病灶在两种扫描上均为阴性。
- 评分2定义为所有病灶均为GaTATE阳性/FDG阴性。
- 评分3定义为所有病灶均为GaTATE阳性但部分或全部同时FDG阳性。
- 评分4定义为存在任何GaTATE阴性/FDG阳性病灶。
- 评分1与评分4被认为不适合PRRT。
临床怎么用
- 原文结论认为双示踪剂分子影像表型可用于选择最适合PRRT的患者,未给出具体推荐等级。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to analyse the molecular imaging (MI) phenotype of typical carcinoid (TC) and atypical carcinoid (AC) by 68Ga-DOTATATE (GaTATE) and 18F-FDG (FDG) PET/CT with the emphasis on its potential theranostic implications for peptide receptor radionuclide therapy (PRRT). METHODS: Retrospective review of patients with biopsy-proven TC or AC undergoing both GaTATE and FDG PET/CT at presentation. Based on correlative CT or MRI, positive lesions on either scan were defined by uptake above liver parenchyma. Per patient MI phenotypic pattern was classified as score 1, if all lesions were negative on both scans; score 2, if all were GaTATE positive/FDG negative; score 3, if all lesions were GaTATE positive but some or all were also FDG positive and score 4, if there were any GaTATE negative/FDG positive lesions. Scores 1 and 4 were deemed unsuitable for PRRT. RESULTS: Of 56 patients (median age 66.5 years, 32 female), 22 had TC, and 34 had AC. Distant metastases were seen in 32% of TC and 94% of AC. At a median follow-up of 37 months for TC and 38 months for AC, 100% and 63% were alive, respectively. Median OS for AC was 56 months (95% CI 43, not reached [NR]), and TC was NR. On inter-patient dual-tracer analysis, scores 1, 2, 3 and 4 were 23%, 18%, 36% and 23% in TC and 3%, 15%, 32% and 50% in AC, respectively. In 16 patients (score 2, N = 3; score 3, N = 12; score 4, N = 1) who were treated with PRRT, disease control rate at 3 months and OS were, 85% and 54.6 months (95% CI 44-70), respectively. CONCLUSIONS: TC and AC showed a wide inter-patient phenotypic heterogeneity on GaTATE and FDG with around half of patients (46% TC and 53% AC) having an unsuitable phenotype for PRRT. Dual-tracer MI phenotype can be used to select the most suitable patients for PRRT.
引用
- Zidan L, Iravani A, Kong G, et al. Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2020. PMID: 32572559. doi:10.1007/s00259-020-04915-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。